A high-stakes legal battle over a controversial puberty blocker trial is heating up, as courts greenlight recruitment of children as young as 11—despite fierce opposition from campaigners who call it unethical and potentially irreversible harm. The High Court rejected efforts to halt the study, commissioned by the former health secretary and led by King’s College London, which aims to track the effects of these drugs on 226 kids. Originally paused over safety concerns after regulators banned them for general use, the trial now resumes with a lower age threshold after compromises with authorities. Critics decry it as dangerous experimentation, while researchers insist strict safeguards and psychological support are in place. The Cass review’s poor-quality research findings may have paved the way—but opponents say this trial risks irreversible damage to vulnerable youth.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
